跳至主要内容
临床试验/CTRI/2010/091/000569
CTRI/2010/091/000569已完成3 期

A multicentric, open label, noncomparetive clinical trial to assess efficacy and safety of a fixed dose combination of meropenam and sulbactam in lower respiratory tract infection caused by Gm (-ve) organisms including Pseudomonas aeruginosa.

MsVHB Medisciences Ltd0 个研究点目标入组 200 人开始时间: 待定最近更新:

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
200

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

入选标准

  • 1. Male and female subjects in the age group of 18-60 years have been selected.
  • 2. Clinically diagnosed subjects lower respiratory infection with Gram (-)ve.
  • 3. Subjects willing to give informed consent.
  • 4. Patient must not have received any antibiotics in previous 4 week.

排除标准

  • 1. History of hypersensitivity reaction or any specific contraindication to ofloxacin or ornidazole or Quinolone group or nitoimidazole group.
  • 2. Presence of hepatic or renal disorders,
  • 3. Pregnancy or lactation,
  • 4. History of hearing loss,
  • 5. Alcoholics
  • 6. Previous history seizure or taking anti epileptic drugs.

研究者

发起方
MsVHB Medisciences Ltd

相似试验